subject:(Hepatitis C)

University of Melbourne

1. Johnson, Douglas Forsyth. An epidemiological to immunological basis for a hepatitis C vaccine.

Degree: 2013, University of Melbourne

► Hepatitis C virus (HCV) is estimated to chronically infect 3% of the world's population [1, 2]. In Australia an estimated 221,000 are living with chronic… (more)

▼ Hepatitis C virus (HCV) is estimated to chronically infect 3% of the world's population [1, 2]. In Australia an estimated 221,000 are living with chronic HCV infection with 10,000 new infections occurring each year, predominantly through injecting drug use (IDU) [2, 3]. Despite the implementation of risk reduction strategies and treatment regimes, HCV transmission rates remain high amongst at risk populations and underscores the pressing need for alternative strategies such as an effective HCV vaccine. This thesis identified at risk populations within Australia that would benefit from an effective HCV vaccine. Subsequently, the immune responses elicited by HCV virus-like-particles (HCV VLPs) were evaluated in a murine model to assess their potential as an HCV vaccine candidate. Firstly, a review of HCV notifications for Victoria, Australia was undertaken utilising surveillance data from the Victorian Department of Health and population estimates from the Australian Bureau of Statistics. Total HCV notifications in Victoria between 2007 and 2011 have fallen from 2782 to 2370 cases (53.3 to 42.1 per 100,000 respectively). Interestingly HCV notifications rates in rural and metropolitan regions of Victoria were similar (46.97 and 44.05 per 100,000 respectively). In contrast HCV treatment rates in rural regions (7.4 - 7.9 per 100,000) were less than half that of metropolitan regions (17.6 - 18.5 per 100,000). Barriers and access to treatment particularly in rural areas need to be addressed as HCV treatment reduces transmission and secondary complications associated with chronic HCV infection. The review of HCV notifications also revealed IDU remains the greatest risk factor for HCV acquisition. Modelling suggests the introduction of an HCV vaccine, particularly in high risk groups such as seronegative IDUs, will have a substantial impact on the incidence of chronic HCV in the community [4-6]. Subsequently, a retrospective cohort study of 361 Australian travellers to Asia demonstrated travellers to endemic countries are also at risk of HCV infection and would benefit from a preventative vaccine. The incidence density of acute HCV infections in this cohort of travellers was 1.8 per 10,000 travel days. The study also identified the incidence density of HBV infection in non immune travellers was 2.19 per 10,000 travel days highlighting the need for both education and vaccination where available. Finally, the immune responses elicited by HCV virus-like-particles in a murine model were evaluated. HCV VLPs were designed in order to elicit the breadth of immune responses that are associated with spontaneous clearance of HCV. HCV VLPs were produced in Huh 7 cells (a human hepatoma cell line) and were shown to bind, enter and mature murine dendritic cells. BALB/c mice vaccinated with HCV VLPs demonstrated the…

Subjects/Keywords: hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Johnson, D. F. (2013). An epidemiological to immunological basis for a hepatitis C vaccine. (Doctoral Dissertation). University of Melbourne. Retrieved from http://hdl.handle.net/11343/37881

Chicago Manual of Style (16^th Edition):

Johnson, Douglas Forsyth. “An epidemiological to immunological basis for a hepatitis C vaccine.” 2013. Doctoral Dissertation, University of Melbourne. Accessed March 02, 2021. http://hdl.handle.net/11343/37881.

MLA Handbook (7^th Edition):

Johnson, Douglas Forsyth. “An epidemiological to immunological basis for a hepatitis C vaccine.” 2013. Web. 02 Mar 2021.

Vancouver:

Johnson DF. An epidemiological to immunological basis for a hepatitis C vaccine. [Internet] [Doctoral dissertation]. University of Melbourne; 2013. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/11343/37881.

Council of Science Editors:

Johnson DF. An epidemiological to immunological basis for a hepatitis C vaccine. [Doctoral Dissertation]. University of Melbourne; 2013. Available from: http://hdl.handle.net/11343/37881

Texas A&M University

2. Klemashevich, Cory. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.

Degree: MS, Chemical Engineering, 2013, Texas A&M University

URL: http://hdl.handle.net/1969.1/149463

► Up to 170 million people are infected with Hepatitis C Virus worldwide. Chronic HCV infection is the leading cause of fibrosis, cirrhosis and liver cancer.… (more)

Subjects/Keywords: Hepatitis C; Dihydropyridine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Klemashevich, C. (2013). Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. (Masters Thesis). Texas A&M University. Retrieved from http://hdl.handle.net/1969.1/149463

Chicago Manual of Style (16^th Edition):

Klemashevich, Cory. “Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.” 2013. Masters Thesis, Texas A&M University. Accessed March 02, 2021. http://hdl.handle.net/1969.1/149463.

MLA Handbook (7^th Edition):

Klemashevich, Cory. “Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus.” 2013. Web. 02 Mar 2021.

Vancouver:

Klemashevich C. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. [Internet] [Masters thesis]. Texas A&M University; 2013. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/1969.1/149463.

Council of Science Editors:

Klemashevich C. Dihydropyridines Inhibit Translation and Early Replication of Hepatitis C Virus. [Masters Thesis]. Texas A&M University; 2013. Available from: http://hdl.handle.net/1969.1/149463

University of Plymouth

3. Mandalou, Paraskevi. Molecular mechanisms of protection from hepatitis C infection.

Degree: Thesis (M.D.), 2018, University of Plymouth

URL: http://hdl.handle.net/10026.1/11610

► Hepatitis C virus (HCV) infection is a major global health burden affecting 1-2% of the world’s population. The majority of infected individuals will develop chronic… (more)

▼ Hepatitis C virus (HCV) infection is a major global health burden affecting 1-2% of the world’s population. The majority of infected individuals will develop chronic infection and are at risk of cirrhosis and hepatocellular carcinoma. There is currently no preventative vaccine available for HCV. In the developed world, the highest HCV incidence and prevalence rate is amongst intravenous drug users (IDU). The duration, frequency of IDU, and sharing of drug injecting equipment contribute to particularly high rates of HCV infection in this population. Individuals at high risk of recurrent exposure to HCV infection from long term IDU have been recruited in Plymouth, UK, from 2003 onwards and if they remain negative for HCV infection are termed exposed uninfected (EU). Understanding the factors that prevent HCV infection in this cohort could give valuable insight into the mechanisms of natural resistance to HCV infection. The EU cohort was previously shown to have characteristics attributable to the activation of both the adaptive and the innate arms of the immune system with no known dominant, immune or non- immune, mechanism of HCV protection. The aim of this thesis was to attempt and identify this mechanism and for that purpose a comparative transcriptional profile study was initially performed between 3 groups: EU, individuals who spontaneously cleared HCV infection (SR) and patients with chronic HCV infection (CHCV). Of the differentially regulated genes, the association with resistance to HCV was strongest for Interleukin-27 (IL-27) which was significantly upregulated in EU compared to the 2 other groups and C X C motif chemokine 7 (CXCL7) which was significantly upregulated in EU relative to the CHCV group. The CD28 mediated T-helper cell signalling pathway was significantly upregulated in SR relative to the 2 other groups. We attempted to corroborate the above findings and we demonstrated that IL-27 is overexpressed in EU, compared to SR and CHCV. The possible role of IL-27 in natural protection from HCV infection remains to be elucidated and requires further study.

Subjects/Keywords: 616.3; Hepatitis C; Vaccine for hepatitis C; Immunology of hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mandalou, P. (2018). Molecular mechanisms of protection from hepatitis C infection. (Doctoral Dissertation). University of Plymouth. Retrieved from http://hdl.handle.net/10026.1/11610

Chicago Manual of Style (16^th Edition):

Mandalou, Paraskevi. “Molecular mechanisms of protection from hepatitis C infection.” 2018. Doctoral Dissertation, University of Plymouth. Accessed March 02, 2021. http://hdl.handle.net/10026.1/11610.

MLA Handbook (7^th Edition):

Mandalou, Paraskevi. “Molecular mechanisms of protection from hepatitis C infection.” 2018. Web. 02 Mar 2021.

Vancouver:

Mandalou P. Molecular mechanisms of protection from hepatitis C infection. [Internet] [Doctoral dissertation]. University of Plymouth; 2018. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/10026.1/11610.

Council of Science Editors:

Mandalou P. Molecular mechanisms of protection from hepatitis C infection. [Doctoral Dissertation]. University of Plymouth; 2018. Available from: http://hdl.handle.net/10026.1/11610

University of Zambia

4. Nchimba, Lweendo. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .

Degree: 2015, University of Zambia

URL: http://hdl.handle.net/123456789/3726

► Background: Sickle Cell Disease (SCD) is highly prevalent in Africans. The SCD trait is 18% in the general population in Zambia and University Teaching Hospital… (more)

▼ Background: Sickle Cell Disease (SCD) is highly prevalent in Africans. The SCD trait is 18% in the general population in Zambia and University Teaching Hospital in Lusaka has under its care over 1500 SCD patients. SCD causes high morbidity and mortality. Patients with SCD often have pathologies that require a blood transfusion. Specific indications for blood transfusion in SCD include acute splenic sequestration, aplastic crises, cardiopulmonary symptoms or signs (e.g. high-output heart failure or hypoxemia), preoperative use, priapism, and life-threatening events that would benefit from improved oxygen delivery such as sepsis, severe infection, acute chest syndrome, stroke, and acute organ ischemia. In addition, blood transfusion remains the first-line therapy for primary and secondary stroke prevention in children with SCD. Transfusion is usually performed when haemoglobin is less than five g/dL. Both hepatitis B and C are blood-borne and therefore can be transmitted by blood transfusion. SCD patients are a special population that requires frequent blood transfusions. Thus, they are prone to acquiring hepatitis B and C. Screening services have greatly reduced the risk of infection via blood transfusion, but transmissions still occur. Methods: A cross-sectional study was done to determine the prevalence of hepatitis B (HBV) and / or hepatitis C (HCV) infection in the SCD population at UTH in Lusaka. Basic demographic characteristics, medical information and laboratory data were collected and used to determine the predictors for hepatitis B and HCV infections in SCD children and adults. A total of 138 patients were screened for Hepatitis B surface antigen, which is a marker for HBV infection, as well as for hepatitis C antibody, the surrogate marker for HCV infection. Human-immuno-deficiency virus or HIV testing was done on all the samples.Findings: Fifty-nine percent of the participants enrolled were female. The mean age at diagnosis was 2years 9 months ± 2.5. The mean haemoglobin level was 7.2g/dL. Only 37% had confirmation of SCD diagnosis on their medical record. HBV prevalence amongst the SCD is 2.2%. Its prevalence is not associated with blood transfusions, age, tattoos or gender. It has a non-significant association with increasing age and sexual activity. HBV infection has been markedly reduced due to vaccination introduced in 2005 in Zambia. The prevalence of HCV is 0.7% and could not be subjected to much statistical manipulation. Conclusion: HBV prevalence amongst the SCD is 2.2%. Its prevalence was not associated with increase in number of blood transfusions. There was a non-significant association between HBV prevalence and increase in age as well as sexual activity. The prevalence of HCV is 0.7%.

Subjects/Keywords: Sickle-Cell Anemia; Hepatitis B; Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Nchimba, L. (2015). Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . (Thesis). University of Zambia. Retrieved from http://hdl.handle.net/123456789/3726

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Nchimba, Lweendo. “Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .” 2015. Thesis, University of Zambia. Accessed March 02, 2021. http://hdl.handle.net/123456789/3726.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Nchimba, Lweendo. “Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia .” 2015. Web. 02 Mar 2021.

Vancouver:

Nchimba L. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . [Internet] [Thesis]. University of Zambia; 2015. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/123456789/3726.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Nchimba L. Prevalence of Hepatitis B and C in Sickle-Cell disease patients at University Teaching Hospital, Lusaka, Zambia . [Thesis]. University of Zambia; 2015. Available from: http://hdl.handle.net/123456789/3726

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

5. Sichone, Victor. Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia.

Degree: 2019, University of Zimbabwe

URL: http://dspace.unza.zm/handle/123456789/6362

► Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV) are a global public health problem which share common risk factors and modes of transmission. Perinatal… (more)

▼ Human Immunodeficiency virus (HIV) and Hepatitis B virus (HBV) are a global public health problem which share common risk factors and modes of transmission. Perinatal transmission is the major route of HBV transmission in endemic areas. Without vaccination, the newborn infant has 10 - 20% risks of developing chronic hepatitis B if the mother is positive for HBsAg, and 90%, if also positive for the HBeAg. The burden of HBV infection in pregnant women at the University Teaching Hospital (UTH) is not known. Hence this study explored the prevalence of HBV infection in HIV positive and HIV negative pregnant women and associated factors. This was a comparative cross-sectional study. A total of 316 pregnant women aged 16-46years were recruited including 158 HIV negative and 158 HIV positive. Recruitment of consenting participants for each subgroup in a 1:1 ratio was done from the antenatal ward until the sample size was attained. A structured questionnaire was administered for socio-demographic data to women with a known HIV status recorded on their antenatal cards. Blood for HBsAg screening were also collected. Data collection was done between 15th Dec 2016 and 30th May, 2017. Of the 316 study participants 11(3.5%) tested positive for HBsAg showing intermediate endemicity. There was no statistical difference in the prevalence of HBV in the HIV negative and HIV positive pregnant women (3.8% and 3.2% respectively, P=0.76. Similarly, there was no association between the age, marital status, parity, residence, religion, education level or form of employment with HBV infection. However, HIV antiretroviral treatment seems to have a protective effect on acquisition of HBV infection [OR = 0.09, CI = 0.01 – 0.63, P = 0.02] Given that no significant differences in the prevalence of HBV in the HIV positive and HIV negative were found, all pregnant women regardless of their HIV status or socio-demographic factors should routinely be screened for Hepatitis B as is recommended by the WHO. Policy makers should make available the Hepatitis B vaccine and Immunoglobulin for infants whose mothers test positive for HBsAg especially those that are also positive for HBeAg. All pregnant women should be counseled on hepatitis B concurrently as the HIV counseling is taking place to increase awareness. All HIV positive women should be encouraged to take antiretroviral drugs as it seems to have a protective effect on the acquisition of HBV infection. A large multi-centre study is, however, necessary to explore this association. Key words: Hepatitis B, Hepatitis C, HIV, Pregnancy

Subjects/Keywords: Hepatitis B; Hepatitis C; HIV – - Pregnancy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sichone, V. (2019). Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia. (Thesis). University of Zimbabwe. Retrieved from http://dspace.unza.zm/handle/123456789/6362

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Sichone, Victor. “Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia.” 2019. Thesis, University of Zimbabwe. Accessed March 02, 2021. http://dspace.unza.zm/handle/123456789/6362.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Sichone, Victor. “Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia.” 2019. Web. 02 Mar 2021.

Vancouver:

Sichone V. Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia. [Internet] [Thesis]. University of Zimbabwe; 2019. [cited 2021 Mar 02]. Available from: http://dspace.unza.zm/handle/123456789/6362.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Sichone V. Prevalence of hepatitis b virus, HIV and HBV Coinfection and associated factors in pregnant women attending antenatal care at the university teaching hospital, Lusaka, Zambia. [Thesis]. University of Zimbabwe; 2019. Available from: http://dspace.unza.zm/handle/123456789/6362

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Newcastle

6. Salmond, Sarah (Ses) Jane. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.

Degree: PhD, 2013, University of Newcastle

URL: http://hdl.handle.net/1959.13/1036900

►

Research Doctorate - Doctor of Philosophy (PhD)

Oxidative stress (OS) is a key mechanism by which liver injury occurs in chronic hepatitis C (CHC) virus… (more)

▼

Research Doctorate - Doctor of Philosophy (PhD)

Oxidative stress (OS) is a key mechanism by which liver injury occurs in chronic hepatitis C (CHC) virus infection. For this Study, it was hypothesised the use of antioxidant compounds would reduce OS, hepatic necroinflammation and hepatic fibrosis in CHC patients. To test this hypothesis, a randomised, double-blind, placebo-controlled clinical trial (termed the 'Hep573 Study') was conducted in three Australian teaching hospitals in New South Wales. One hundred and eighteen participants were recruited through the liver outpatient clinics at the hospitals from July, 2003 to March, 2006. They were randomised to treatment in blocks of six to one of three groups: placebo; silymarin (720 mg silybin/day); and silymarin with antioxidants (720 mg silybin plus 13 other ingredients). Study duration was 48 weeks: 24 weeks on active treatment or placebo, and 24 weeks follow-up post treatment. The primary outcome measure was the proportion of patients with alanine aminotransferase (ALT) normalisation at Week 24 (Fisher‟s exact test). Secondary outcome measures were the percentage change from baseline to Week 24 in F₂₋isoprostanes, and to Week 24 and Week 48 in ALT, HCV viral load (HCV RNA) and FibroTest (Linear Mixed Effects). Results were analysed on an intention-to-treat basis. In patients with compensated CHC, the use of silymarin and antioxidant compounds achieved a higher rate of ALT normalisation than placebo (P=0.02) or silymarin (P=0.003) at Week 24. This result could not be attributed to alcohol, diet or caffeine, as intake across the groups did not change throughout the Study. In addition, there was a significant improvement in the overall mental-health score (Mental Component Summary), QualityMetric Hepatitis Quality of Life Questionnaire™ (HQLQ) in the silymarin and antioxidant (SOX) group (P=0.002). This novel randomised, double-blind, placebo-controlled trial of oral silymarin and oral antioxidants has shown a reduction in hepatic necroinflammation and an improvement in overall mental-health status in a specific CHC population.

Advisors/Committee Members: University of Newcastle. Faculty of Health & Medicine, School of Medicine and Public Health.

Subjects/Keywords: silymarin; antioxidants; chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Salmond, S. (. J. (2013). The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. (Doctoral Dissertation). University of Newcastle. Retrieved from http://hdl.handle.net/1959.13/1036900

Chicago Manual of Style (16^th Edition):

Salmond, Sarah (Ses) Jane. “The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.” 2013. Doctoral Dissertation, University of Newcastle. Accessed March 02, 2021. http://hdl.handle.net/1959.13/1036900.

MLA Handbook (7^th Edition):

Salmond, Sarah (Ses) Jane. “The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C.” 2013. Web. 02 Mar 2021.

Vancouver:

Salmond S(J. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. [Internet] [Doctoral dissertation]. University of Newcastle; 2013. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/1959.13/1036900.

Council of Science Editors:

Salmond S(J. The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C. [Doctoral Dissertation]. University of Newcastle; 2013. Available from: http://hdl.handle.net/1959.13/1036900

Kwame Nkrumah University of Science and Technology

7. Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.

Degree: 2014, Kwame Nkrumah University of Science and Technology

URL: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

►

The hepatitis C virus (HCV), which was not recognized as an infectious agent until the 1980s, is responsible for a worldwide epidemic. The World Health… (more)

Subjects/Keywords: Africa; epidemiology; hepatitis C; transmission.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, B. L. (2014). Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. (Thesis). Kwame Nkrumah University of Science and Technology. Retrieved from http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. “Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.” 2014. Thesis, Kwame Nkrumah University of Science and Technology. Accessed March 02, 2021. http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako, Babatunde L. “Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention.” 2014. Web. 02 Mar 2021.

Vancouver:

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako BL. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. [Internet] [Thesis]. Kwame Nkrumah University of Science and Technology; 2014. [cited 2021 Mar 02]. Available from: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Layden, Jennifer E.; Phillips, Richard O.; Opare-Sem, Ohene; Akere, Adegboyega; Salako BL. Hepatitis C in Sub-Saharan Africa: Urgent Need for Attention. [Thesis]. Kwame Nkrumah University of Science and Technology; 2014. Available from: http://dspace.knust.edu.gh:8080/jspui/handle/123456789/11854

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Adelaide

8. Jagdale, Harshwardhan. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.

Degree: 2016, University of Adelaide

URL: http://hdl.handle.net/2440/112856

► Hepatitis C virus (HCV) infects over 200 million people worldwide and results in persistent infection of approximately 80% of cases. Consequently, HCV is a leading… (more)

▼ Hepatitis C virus (HCV) infects over 200 million people worldwide and results in persistent infection of approximately 80% of cases. Consequently, HCV is a leading global contributor to severe liver disease. Although, direct-acting antiviral agents (DAA) are available, these drugs do not prevent re-infection and cost in excess of US $80, 000 per patient. Thus, the development of an inexpensive HCV vaccine represents the most effective measure to reduce the current epidemic. Patients who recover following acute HCV infections provide valuable clues for vaccine design. These patients develop a broad and sustained cell-mediated immunity (CMI) against multiple HCV proteins, in particular the non-structural (NS) proteins. Therefore, the focus of this thesis was to develop novel vaccine strategies to elicit CMI against HCV NS proteins which may mimic the immunity that facilitates spontaneous control of acute HCV infection. Dendritic cells (DC) are crucial to initiate CMI making these cells attractive targets for any vaccine. Recombinant porcine adenoviruses (rPAV) appear capable of targeting DC as rPAV encoding influenza virus antigens have been shown to elicit both humoral and CMI. Furthermore, rPAV are not infectious nor replicate in humans making them safe. The potential of rPAV to elicit HCV-specific CMI is unknown. Therefore, I attempted to construct a cytolytic rPAV encoding a lytic protein as the cytolytic nature of viruses significantly augments immunogenicity due to the release of natural adjuvants known as danger associated molecular patters (DAMPs) from infected cells. As a prelude to this aim, the lytic activity of two cytolytic proteins, namely adenovirus death protein (ADP) from AD5 and mouse perforin (PRF) were compared following transfection of HEK293T cells with pVAX DNA encoding ADP or PRF (chapter 3). In two independent cell death assays (viz. luciferase assay and lactate dehydrogenase release assay), it was determined that PRF was more lytic, making it a suitable protein to be encoded in a lytic rPAV HCV vaccine. I then attempted to modify the rPAV shuttle DNA to facilitate cloning and expression of HCV NS antigens. Initially, the efficiency of the truncated CMV (tCMV) promoter and the full-length CMV (fCMV) promoter to drive eGFP expression was compared. Using flow cytometry and confocal microscopy, the tCMV promoter was shown to be more efficient. In addition, the rPAV shuttle DNA was modified to contain a multiple cloning site to facilitate gene insertion. Subsequently, recombinant PAV plasmids encoding PRF controlled by the tCMV or SV40 promoters were constructed, but recombinant virus was not recovered. This is most likely because PRF killed the cells prior to virus assembly. Subsequently, several experiments were conducted (Chapter 5) with a reporter virus encoding LUC and eGFP and established that rPAV production requires early passage cells (P11) cultured for 10-14 days post transfection. Based on these results, a non-lytic rPAV devoid of PRF was constructed to elicit CMI to conserved HCV NS… Advisors/Committee Members: Gowans, Eric James (advisor), Wijesundara, Danushka (advisor), Grubor-Bauk, Branka (advisor), School of Medicine (school).

Subjects/Keywords: Hepatitis C; adenovirus; vaccine

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jagdale, H. (2016). Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. (Thesis). University of Adelaide. Retrieved from http://hdl.handle.net/2440/112856

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Jagdale, Harshwardhan. “Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.” 2016. Thesis, University of Adelaide. Accessed March 02, 2021. http://hdl.handle.net/2440/112856.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Jagdale, Harshwardhan. “Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.” 2016. Web. 02 Mar 2021.

Vancouver:

Jagdale H. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. [Internet] [Thesis]. University of Adelaide; 2016. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/2440/112856.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Jagdale H. Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus. [Thesis]. University of Adelaide; 2016. Available from: http://hdl.handle.net/2440/112856

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Debrecen

9. Nandul Durfa, Damcit. Hepatitis c and Treatment .

Degree: DE – Általános Orvostudományi Kar, University of Debrecen

URL: http://hdl.handle.net/2437/230508

► ABSTRACT Hepatitis C is a global epidemic that affects over 150 million people. The global prevalence of HCV infection is approximately 2.2 - 3% of… (more)

Subjects/Keywords: hepatitis c

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Nandul Durfa, D. (n.d.). Hepatitis c and Treatment . (Thesis). University of Debrecen. Retrieved from http://hdl.handle.net/2437/230508

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Nandul Durfa, Damcit. “Hepatitis c and Treatment .” Thesis, University of Debrecen. Accessed March 02, 2021. http://hdl.handle.net/2437/230508.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Nandul Durfa, Damcit. “Hepatitis c and Treatment .” Web. 02 Mar 2021.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Nandul Durfa D. Hepatitis c and Treatment . [Internet] [Thesis]. University of Debrecen; [cited 2021 Mar 02]. Available from: http://hdl.handle.net/2437/230508.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

Nandul Durfa D. Hepatitis c and Treatment . [Thesis]. University of Debrecen; Available from: http://hdl.handle.net/2437/230508

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Queen Mary, University of London

10. Cunningham, Morven Elizabeth. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.

Degree: PhD, 2016, Queen Mary, University of London

URL: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

► Chronic infection with hepatitis C virus (HCV) is a significant global health problem, with approximately 170 million individuals infected worldwide. Treatment is rapidly evolving to… (more)

▼ Chronic infection with hepatitis C virus (HCV) is a significant global health problem, with approximately 170 million individuals infected worldwide. Treatment is rapidly evolving to combinations of highly potent direct-acting antiviral drugs, although optimal combinations for individual patient groups are not yet clear. Treatment failure still occurs, and relapse may occur in as many as 10% of treated individuals. Whilst HCV replicates primarily in the liver, HCV RNA has been identified in extrahepatic sites, including monocytes, although extrahepatic replication is controversial. Our group recently developed a novel assay to study replication of patient-derived HCV by fusion of patient monocytes with cultured hepatoma cells. In this study, we extended the utility of this fusion model, by using cell culture monocytes to 'capture' HCV from patient serum prior to fusion with hepatoma cells. We studied whether this 'capture-fusion' model could be used to screen individual patient drug response and the mechanisms permitting viral replication in the hybrid cells. Using the capture-fusion assay, patient-derived HCV of all viral genotypes replicated to levels detectable by a sensitive PCR assay and could be inhibited by antiviral drugs in a genotype-specific manner. Isolates with genotypic and phenotypic drug resistance could be identified, and, in a blinded study, drug sensitivity in the assay correlated with clinical treatment response. Relapse after interferon and ribavirin treatment was associated with poor pre-treatment ribavirin sensitivity and also with viable HCV in patient-derived monocytes at the end of therapy. Uptake of HCV into monocytes appeared independent of classical HCV entry receptors, and our work implicated CD64 in HCV monocyte entry. Cell fusion appeared to permit transfer of HCV RNA to hepatocytes without triggering an intracellular antiviral innate immune response. Our data suggest that this novel 'capture-fusion' model represents a promising new technique which may help identify appropriate treatment strategies for patients with chronic HCV infection.

Subjects/Keywords: Hepatitis C; capture-fusion assay

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Cunningham, M. E. (2016). Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. (Doctoral Dissertation). Queen Mary, University of London. Retrieved from http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

Chicago Manual of Style (16^th Edition):

Cunningham, Morven Elizabeth. “Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.” 2016. Doctoral Dissertation, Queen Mary, University of London. Accessed March 02, 2021. http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196.

MLA Handbook (7^th Edition):

Cunningham, Morven Elizabeth. “Developing new models to predict treatment outcome in patients with chronic hepatitis C infection.” 2016. Web. 02 Mar 2021.

Vancouver:

Cunningham ME. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. [Internet] [Doctoral dissertation]. Queen Mary, University of London; 2016. [cited 2021 Mar 02]. Available from: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196.

Council of Science Editors:

Cunningham ME. Developing new models to predict treatment outcome in patients with chronic hepatitis C infection. [Doctoral Dissertation]. Queen Mary, University of London; 2016. Available from: http://qmro.qmul.ac.uk/xmlui/handle/123456789/12753 ; https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.775196

University of Victoria

11. Zukowski, Phyllis Donna. Women’s experiences of receiving a diagnosis and living with Hepatitis C.

Degree: School of Nursing, 2011, University of Victoria

URL: http://hdl.handle.net/1828/3595

► This research explores the lived experiences of what it means to women when they receive a diagnosis of Hepatitis C (HCV). The approach to guide… (more)

Subjects/Keywords: Hepatitis C; women; Nursing

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zukowski, P. D. (2011). Women’s experiences of receiving a diagnosis and living with Hepatitis C. (Masters Thesis). University of Victoria. Retrieved from http://hdl.handle.net/1828/3595

Chicago Manual of Style (16^th Edition):

Zukowski, Phyllis Donna. “Women’s experiences of receiving a diagnosis and living with Hepatitis C.” 2011. Masters Thesis, University of Victoria. Accessed March 02, 2021. http://hdl.handle.net/1828/3595.

MLA Handbook (7^th Edition):

Zukowski, Phyllis Donna. “Women’s experiences of receiving a diagnosis and living with Hepatitis C.” 2011. Web. 02 Mar 2021.

Vancouver:

Zukowski PD. Women’s experiences of receiving a diagnosis and living with Hepatitis C. [Internet] [Masters thesis]. University of Victoria; 2011. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/1828/3595.

Council of Science Editors:

Zukowski PD. Women’s experiences of receiving a diagnosis and living with Hepatitis C. [Masters Thesis]. University of Victoria; 2011. Available from: http://hdl.handle.net/1828/3595

University of Minnesota

12. Sweet Kennedy, Kristin. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.

Degree: PhD, Health Services Research, Policy and Administration, 2014, University of Minnesota

URL: http://hdl.handle.net/11299/174894

► Hepatitis C (HCV) infection is the most common bloodborne illness in the United States and the prevalence is highest in those born between 1945 and… (more)

Subjects/Keywords: Hepatitis C; Hepatocellular Carcinoma

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sweet Kennedy, K. (2014). Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. (Doctoral Dissertation). University of Minnesota. Retrieved from http://hdl.handle.net/11299/174894

Chicago Manual of Style (16^th Edition):

Sweet Kennedy, Kristin. “Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.” 2014. Doctoral Dissertation, University of Minnesota. Accessed March 02, 2021. http://hdl.handle.net/11299/174894.

MLA Handbook (7^th Edition):

Sweet Kennedy, Kristin. “Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment.” 2014. Web. 02 Mar 2021.

Vancouver:

Sweet Kennedy K. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. [Internet] [Doctoral dissertation]. University of Minnesota; 2014. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/11299/174894.

Council of Science Editors:

Sweet Kennedy K. Hepatitis C: Hepatocellular carcinoma, mortality, and the impact of treatment. [Doctoral Dissertation]. University of Minnesota; 2014. Available from: http://hdl.handle.net/11299/174894

University of New South Wales

13. Martinello, Marianne. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.

Degree: Kirby Institute, 2017, University of New South Wales

URL: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

► Background: The management of recent hepatitis C virus (HCV) infection is uncertain, as the therapeutic landscape evolves with the advent of direct-acting antiviral (DAA) therapy.Aims:… (more)

▼ Background: The management of recent hepatitis C virus (HCV) infection is uncertain, as the therapeutic landscape evolves with the advent of direct-acting antiviral (DAA) therapy.Aims: The broad aim of this research was to examine novel therapeutic strategies in recent HCV following the availability of DAA therapy. Specific aims included assessing the feasibility, efficacy and safety of response-guided interferon (IFN)-containing and ultra-short IFN-free therapy; calculating reinfection incidence following treatment; and determining the clinical significance of drug-drug interactions in HIV/HCV co-infection.Methods: In Chapters Two and Three, the efficacy and safety of short and/or response-guided treatment among individuals with recent HCV was examined in three open-label trials: ATAHC II (n=52; pegylated-IFN +/- ribavirin), DARE-C I (n=14; pegylated-IFN, ribavirin + telaprevir) and DARE-C II (n=19; sofosbuvir + ribavirin). In Chapter Four, reinfection incidence following treatment for recent HCV was calculated among those who achieved an end-of-treatment response in ATAHC I and II, DARE-C I and II (n=120). In Chapter Five, a simulation of potential drug-drug interactions between combination antiretroviral therapy and DAAs was performed in those with HIV/HCV enrolled in CEASE-D (n=257).Key Findings: A total of 85 individuals (73% HIV) with recent HCV commenced short and/or response-guided treatment between 2010 and 2015; none of the strategies trialled was optimal. Given toxicity, the applicability of an IFN-containing strategy is limited. Conversely, six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was poor. High reinfection incidence, particularly in individuals reporting injection drug use following treatment, was seen. These trials confirmed the feasibility of short duration therapy in recent HCV and informed contemporary trial design. Optimal DAA regimen choice for future research will be crucial; the combination of a nucleotide analogue and an NS5A inhibitor appears appropriate given potency and little potential for drug-drug interactions in HIV/HCV co-infection.Conclusion: The role and efficacy of ultra-short duration therapy in recent HCV requires further evaluation with potent DAA regimens. The significant risk for HCV reinfection following treatment in individuals with ongoing behaviour facilitating transmission emphasises the need for post-treatment surveillance, harm reduction strategies and education. Advisors/Committee Members: Matthews, Gail, Kirby Institute, Faculty of Medicine, UNSW, Dore, Gregory, Kirby Institute, Faculty of Medicine, UNSW.

Subjects/Keywords: Treatment; Hepatitis C; Acute

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Martinello, M. (2017). Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. (Doctoral Dissertation). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

Chicago Manual of Style (16^th Edition):

Martinello, Marianne. “Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.” 2017. Doctoral Dissertation, University of New South Wales. Accessed March 02, 2021. http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true.

MLA Handbook (7^th Edition):

Martinello, Marianne. “Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy.” 2017. Web. 02 Mar 2021.

Vancouver:

Martinello M. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. [Internet] [Doctoral dissertation]. University of New South Wales; 2017. [cited 2021 Mar 02]. Available from: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true.

Council of Science Editors:

Martinello M. Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy. [Doctoral Dissertation]. University of New South Wales; 2017. Available from: http://handle.unsw.edu.au/1959.4/57843 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:45003/SOURCE02?view=true

Rutgers University

14. Wang, Yuanyuan, 1991-. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.

Degree: PhD, Chemistry and Chemical Biology, 2019, Rutgers University

URL: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

►

Hepatitis C is a liver disease caused by hepatitis C virus (HCV). HCV is the major cause of cirrhosis and hepatocellular cancer in the US… (more)

▼

Hepatitis C is a liver disease caused by hepatitis C virus (HCV). HCV is the major cause of cirrhosis and hepatocellular cancer in the US and is the number one cause of liver transplantation. An estimate of 3.5 million people is chronically infected in the US with 400,000 individuals deaths from chronic HCV infection every year. Several direct-acting antiviral (DAA) agents have been approved by the Food and Drug Administration (FDA). HCV is a blood-borne virus, which prior to 1992 was transmitted through blood transfusion. An estimated 41,200 new cases of HCV infection occurred in the US with an additional 1.75 million worldwide in 2016. Therefore, there is an urgent need to control the transmission of HCV, in addition to the antiviral intervention to limit the spread of the virus. Vaccination is the most effective way to control the infection rate as no infectious disease has ever been eradicated by treatment alone. However, no vaccine is available to prevent HCV infection. A useful mammalian cell expression system was described to produce HCV envelope glycoproteins E1 and E2, as well as the cell surface receptors, scavenger receptor class B type I (SRB1) and cluster of differentiation 81 (CD81). Our method combines the speed and high efficiency of lentiviral infection with an adherent cell bioreactor to allow large-scale production of proteins in mammalian cell lines. The full-length ectodomain of HCV E1 was produced at milligram quantity and is recognized by conformational antibodies from patient samples. E1 can associate with the apolipoproteins from the cell culture serum. HCV E2 produced by the mammalian cell expression system has the function to bind cell surface receptors and antibodies. Crystals of E2 and CD81 diffract to 4.3 Å resolution allowing us to produce a low-resolution model of the E2-receptor complex. Overall, our result extends the current understanding of HCV entry by providing more structural, biophysical, and functional information on the HCV glycoproteins. The studies of the receptor interaction can contribute to vaccine design to halt the spread of HCV infection.

Advisors/Committee Members: Marcotrigiano, Joseph (chair), Case, David (internal member), Baum, Jean (internal member), Arnold, Eddy (internal member), Cohen, Jeffrey (outside member), School of Graduate Studies.

Subjects/Keywords: Hepatitis C virus – Treatment

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Wang, Yuanyuan, 1. (2019). Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. (Doctoral Dissertation). Rutgers University. Retrieved from https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

Chicago Manual of Style (16^th Edition):

Wang, Yuanyuan, 1991-. “Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.” 2019. Doctoral Dissertation, Rutgers University. Accessed March 02, 2021. https://rucore.libraries.rutgers.edu/rutgers-lib/60087/.

MLA Handbook (7^th Edition):

Wang, Yuanyuan, 1991-. “Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system.” 2019. Web. 02 Mar 2021.

Vancouver:

Wang, Yuanyuan 1. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. [Internet] [Doctoral dissertation]. Rutgers University; 2019. [cited 2021 Mar 02]. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/.

Council of Science Editors:

Wang, Yuanyuan 1. Overcoming challenges on HCV glycoproteins and receptors production: a useful mammalian cell expression system. [Doctoral Dissertation]. Rutgers University; 2019. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/60087/

Universidade Federal de Mato Grosso do Sul

15. Tetila, Andyane Freitas. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .

Degree: 2011, Universidade Federal de Mato Grosso do Sul

URL: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

► A infecção pelo vírus da hepatite C (HCV) não é rara em indivíduos infectados pelo vírus da imunodeficiência humana (HIV) e representa um importante problema… (more)

Subjects/Keywords: HIV; Coinfecção; Coinfection; Hepatite C; Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tetila, A. F. (2011). Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . (Thesis). Universidade Federal de Mato Grosso do Sul. Retrieved from http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Tetila, Andyane Freitas. “Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .” 2011. Thesis, Universidade Federal de Mato Grosso do Sul. Accessed March 02, 2021. http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Tetila, Andyane Freitas. “Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C .” 2011. Web. 02 Mar 2021.

Vancouver:

Tetila AF. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . [Internet] [Thesis]. Universidade Federal de Mato Grosso do Sul; 2011. [cited 2021 Mar 02]. Available from: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Tetila AF. Características clínico-epidemiológicas e fatores associados à infecção pelo HIV em portadores da Hepatite Crônica C . [Thesis]. Universidade Federal de Mato Grosso do Sul; 2011. Available from: http://repositorio.cbc.ufms.br:8080/jspui/handle/123456789/1847

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

16. Calland, Noémie. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.

Degree: Docteur es, Biochimie et biologie moléculaire, 2012, Université Lille II – Droit et Santé

URL: http://www.theses.fr/2012LIL2S031

► L’hépatite C est un problème majeur de santé publique qui touche environ 160 millions de personnes dans le monde. L’agent étiologique responsable de cette maladie,… (more)

▼ L’hépatite C est un problème majeur de santé publique qui touche environ 160 millions de personnes dans le monde. L’agent étiologique responsable de cette maladie, le virus de l’hépatite C (HCV), est un petit virus enveloppé dont le génome est codé par un acide ribonucléique (ARN) simple brin de polarité positive. Actuellement, il n’existe aucun vaccin contre ce pathogène et les traitements utilisés sont insatisfaisants du fait de leur spécificité d’action limitée. Ainsi, afin d’établir une thérapie antivirale efficace évitant l’apparition et la sélection de mutants de résistance aux antiviraux, l’utilisation de plusieurs agents antiviraux ciblant directement la particule virale (direct acting antiviral agents ou DAAs) en combinaison est préconisée. C’est pourquoi la découverte de nouveaux DAAs à large spectre d’action ciblant diverses étapes du cycle viral infectieux est indispensable.Au cours de ma thèse, nous avons identifié un nouvel inhibiteur de l’entrée du HCV : l’épigallocatéchine-3-gallate (EGCG). Cette molécule, extraite du thé vert, inhibe l’infection des cellules par le HCV. Plus précisément, en utilisant des particules rétrovirales pseudotypées avec les glycoprotéines d’enveloppe E1 et E2 du HCV, nous avons démontré que cette catéchine naturelle, agit à une étape très précoce de l’entrée virale, indépendamment du génotype. De même, en nous servant du virus produit en culture cellulaire, nous avons montré que cette molécule agit directement sur la particule virale. Puis, par RT-PCR quantitative (quantitative real-time polymerase chain reaction), nous avons confirmé l’inhibition de la liaison du virus à la surface cellulaire, en présence d’EGCG. Par conséquent, nos travaux suggèrent que l’EGCG interagit avec la particule virale, probablement en se liant aux glycoprotéines d’enveloppe virales, bloquant ainsi une étape initiale d’attachement entre le virus et les facteurs cellulaires présents à la surface de l’hépatocyte. Puis, en inhibant la transmission libre du virus, à l’aide, soit d’agarose, soit d’anticorps neutralisants, nous avons démontré que l’EGCG inhibe la transmission du virus de cellule à cellule. Enfin, nous avons montré que l’EGCG élimine le virus présent dans le surnageant de culture cellulaire après quatre passages successifs sur des cellules naïves.La concentration d’EGCG nécessaire pour inhiber la moitié de l’infection virale (IC50) en culture cellulaire est 11 µM. Ainsi, afin d’identifier de nouvelles molécules présentant un mode d’action similaire à celui de l’EGCG et possédant une meilleure activité antivirale, nous avons sélectionnés différentes molécules naturelles et les avons testés pour leur potentiel effet anti-HCV. C’est ainsi que le chlorure de delphinidine, une anthocyanidine, a également été identifié en tant que nouvelle molécule inhibitrice de l’entrée du HCV. De même que l’EGCG, le chlorure de delphinidine cible directement la particule virale à une étape précoce de l’entrée, indépendamment du génotype, probablement en inhibant l’attachement du virus à la surface… Advisors/Committee Members: Séron, Karin (thesis director).

Subjects/Keywords: EGCG; Delphinidine; Hépatite C; Hepatitis C virus

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Calland, N. (2012). L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. (Doctoral Dissertation). Université Lille II – Droit et Santé. Retrieved from http://www.theses.fr/2012LIL2S031

Chicago Manual of Style (16^th Edition):

Calland, Noémie. “L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.” 2012. Doctoral Dissertation, Université Lille II – Droit et Santé. Accessed March 02, 2021. http://www.theses.fr/2012LIL2S031.

MLA Handbook (7^th Edition):

Calland, Noémie. “L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry.” 2012. Web. 02 Mar 2021.

Vancouver:

Calland N. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. [Internet] [Doctoral dissertation]. Université Lille II – Droit et Santé 2012. [cited 2021 Mar 02]. Available from: http://www.theses.fr/2012LIL2S031.

Council of Science Editors:

Calland N. L'EGCG et la delphinidine : deux nouvelles molécules naturelles inhibant l'entrée du virus de l'hépatite C : EGCG and delphinidin : two new natural inhibitors of hepatitis C virus entry. [Doctoral Dissertation]. Université Lille II – Droit et Santé 2012. Available from: http://www.theses.fr/2012LIL2S031

17. Kotsiri, Ioanna. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.

Degree: 2016, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/37543

►

Summary: TGF-β1 is an important pre-fibrinogenic cytokine, which is produced by the non-parenchymal liver cells, activates the hepatic asteroid cells and has been involved in… (more)

▼

Summary: TGF-β1 is an important pre-fibrinogenic cytokine, which is produced by the non-parenchymal liver cells, activates the hepatic asteroid cells and has been involved in the pathogenesis of liver fibrosis. For that reason, its role in the evolution of liver fibrosis has been studied for many years in patients with chronic hepatitis C (CHC) as well as with chronic hepatitis B. The purpose of this dissertation was to study the serum TGF-β1 levels, in association with liver fibrosis and to examine their change according to treatment response and their value as a predictive index in patients with CHC under antiviral treatment.Eighty four patients were included in the study (average age 46 years- old, 44 men, 40 women) with CHC belonging to all known HCV genotypes and were treated with pegylated interferon plus ribavirin. Liver fibrosis was estimated non-invasively with liver transient elastography. TGF-β1 levels were measured before and at the end of follow-up and 6 months after the completion of antiviral therapy using a standard immunoassay.TGF-β1 levels were not associated with epidemiological, biochemical or virological parameters. Univariate analysis showed association between antiviral treatment, age and white blood count, but not with the initial TGF-β1 levels. For patients with sustained virological response (SVR) TGF-β1 levels were significantly decreased at the end (12.327 pg/ml, p<0.0001) and 6 months after the completion of antiviral therapy (13.555 pg/ml, p=0.007) compared to baseline values (17.166 pg/ml), but not in patients showing relapse (11.487 vs 12.241 or 9.648 pg/ml, p=0.814 or p=0.344) or in patients showing non-response (16.319 vs 11.362 or 11.977 pg/ml, p=0.227 or p=0.695). There was no association between TGF-β1 and degree of liver fibrosis as estimated with transient elastography at baseline (p=0.29).In conclusion, our results shown that TGF-β1 displayed significant decrease in CHC patients with SVR to antiviral therapy. TGF-β1 levels are not associated with degree of liver fibrosis or to response to antiviral treatment.

ΠΕΡΙΛΗΨΗ: Ο TGF-β1 είναι μια σημαντική προ-ινωδογόνος κυτταροκίνη, παράγεται από τα μη παρεγχυματικά ηπατοκύτταρα, ενεργοποιεί τα ηπατικά αστεροειδή κύτταρα και έχει εμπλακεί στην παθογένεση της ηπατικής ίνωσης. Γι΄αυτό, ο ρόλος του στην εξέλιξη της ηπατικής ίνωσης έχει μελετηθεί για πολλά χρόνια, σε ασθενείς με χρόνια ηπατίτιδα C (CΗC) όσο και με χρόνια ηπατίτιδα B.Σκοπός της παρούσας διατριβής ήταν η μελέτη των επιπέδων του TGF-β1 στον ορό, η συσχέτισή τους με την ηπατική ίνωση, η μεταβολή τους ανάλογα με την ανταπόκριση στη θεραπεία, και η αξία του ως προγνωστικός δείκτης σε ασθενείς με χρόνια ηπατίτιδα C (CΗC) υπό αντιική θεραπεία.Στην μελέτη εντάχθηκαν 84 ασθενείς (μέση ηλικία 46 έτη, 44 άνδρες/40 γυναίκες) με ΧΗC όλων των γονοτύπων και τους χορηγήθηκε συνδυασμένη θεραπεία με πεγκυλιωμένη ιντερφερόνη και ριμπαβιρίνη. Η ηπατική ίνωση εκτιμήθηκε μη επεμβατικά με ελαστογραφία ήπατος. Τα επίπεδα του TGF-β1 στον ορό μετρήθηκαν πριν την έναρξη, στο τέλος και στους 6…

Subjects/Keywords: Χρόνια ηπατίτιδα C; Chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Kotsiri, I. (2016). Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/37543

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Kotsiri, Ioanna. “Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.” 2016. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed March 02, 2021. http://hdl.handle.net/10442/hedi/37543.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Kotsiri, Ioanna. “Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα.” 2016. Web. 02 Mar 2021.

Vancouver:

Kotsiri I. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2016. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/10442/hedi/37543.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Kotsiri I. Η σημασία του μετατρεπτικού αυξητικού παράγοντα β (tgf-β1) στη χρόνια ιογενή ηπατίτιδα. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2016. Available from: http://hdl.handle.net/10442/hedi/37543

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

18. Polydoros, Konstantinides. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.

Degree: 2019, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)

URL: http://hdl.handle.net/10442/hedi/46058

►

Several studies have provided conflicting results regarding the immune responses in chronic hepatitis C (CHC) patients with mixed cryoglobulinemia (MC). The importance of B-cell activating… (more)

▼

Several studies have provided conflicting results regarding the immune responses in chronic hepatitis C (CHC) patients with mixed cryoglobulinemia (MC). The importance of B-cell activating factor (BAFF) in MC has been described, but the role of interleukin (IL)-17A is less clear. Aim of the Study: The main objectives were to determine the levels of BAFF and IL-17A cytokines in patients with CHC with or without MC, and to investigate their kinetics during antiviral treatment with pegylated interferon-α/ribavirin and 6 months after the end of it. In addition, the aim was to evaluate the possible correlation of cytokines with vitD levels, the degree of hepatic fibrosis and the response to antiviral therapy. Furthermore, the results were correlated with demographic and laboratory data of the patients under study.Methods: Serum concentrations of IL-17A, BAFF and 25-OH vitamin D were measured in 34 CHC patients at baseline, end of treatment, and 6 months post-treatment with pegylated interferon-α and ribavirin, versus 12 healthy controls.Results: Thirty-four patients (20 male, mean age 40.7±9.2 years, 12 of genotype 1 or 4, 22 of genotype 2 or 3) were included, of whom 64.7% achieved a sustained virological response (SVR). MC was detected in 52.9% of the patients. Higher levels of both cytokines were found in patients with MC compared to those without. Patients who achieved SVR had higher pretreatment IL-17A and lower BAFF levels compared to those without SVR. IL-17A was downregulated during and following treatment in responders, whereas upregulation was observed in non-responders. CHC patients demonstrated low vitamin D levels compared to HC. Moreover, the changes in IL-17A over the treatment period were significantly associated with vitamin D changes (β=-0.04, SE=0.02, P=0.046). No difference in IL-17A, BAFF and vitamin D values was seen between patients with cirrhosis (n=14) and those without.Conclusions: CHC patients with asymptomatic MC have increased levels of IL-17A and BAFF. IL-17A levels decline significantly while BAFF increases during treatment in responders. An interplay between IL-17A and vitamin D concentrations was revealed during the antiviral treatment.Keywords: Interleukin 17A, B-cell activating factor, vitamin D, chronic hepatitis C, mixed cryoglobulinemia

Αρκετές μελέτες παρουσίασαν αντικρουόμενα αποτελέσματα σχετικά με τις ανοσολογικές αντιδράσεις σε ασθενείς με χρόνια ηπατίτιδα C (CHC) και μικτή κρυοσφαιριναιμία (MC). Η σημασία του ενεργοποιητικού παράγοντα των Β λεμφοκυττάρων (BAFF) στη MC έχει περιγραφεί προηγουμένως, αλλά ο ρόλος της ιντερλευκίνης (IL)-17A είναι λιγότερο σαφής. Σκοπός: Οι κύριοι στόχοι της παρούσας μελέτης ήταν ο προσδιορισμός των επιπέδων των κυτταροκινών BAFF και IL-17A σε ασθενείς που πάσχουν από CHC με ή χωρίς MC, και η διερεύνηση της κινητικής τους κατά τη διάρκεια της αντιιικής θεραπείας με pegIFN/RBV και 6 μήνες μετά το τέλος αυτής. Επιπρόσθετα, θέλαμε να αξιολογήσουμε τη σχέση των κυτταροκινών με τα επίπεδα της vitD, το βαθμό της ηπατικής ίνωσης και την ανταπόκριση στην…

Subjects/Keywords: Χρόνια ηπατίτιδα C; Chronic hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Polydoros, K. (2019). Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. (Thesis). National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Retrieved from http://hdl.handle.net/10442/hedi/46058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Polydoros, Konstantinides. “Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.” 2019. Thesis, National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Accessed March 02, 2021. http://hdl.handle.net/10442/hedi/46058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Polydoros, Konstantinides. “Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D.” 2019. Web. 02 Mar 2021.

Vancouver:

Polydoros K. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. [Internet] [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2019. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/10442/hedi/46058.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Polydoros K. Η ιντερλευκίνη-17Α και ο ενεργοποιητικός παράγοντας των Β λεμφοκυττάρων σε ασθενείς με χρόνια ηπατίτιδα C και μικτή κρυοσφαιριναιμία: επιδράσεις της αντιιικής θεραπείας και συσχετίσεις με τη βιταμίνη D. [Thesis]. National and Kapodistrian University of Athens; Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ); 2019. Available from: http://hdl.handle.net/10442/hedi/46058

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

19. Karamichali, Eirini. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.

Degree: 2014, University of Patras; Πανεπιστήμιο Πατρών

URL: http://hdl.handle.net/10442/hedi/35595

►

HCV infection is a major public health problem and a leading cause of chronic liver disease and hepatocellular carcinoma, with approximately 180 million infected individuals… (more)

▼

HCV infection is a major public health problem and a leading cause of chronic liver disease and hepatocellular carcinoma, with approximately 180 million infected individuals worldwide. HCV is a positive sense RNA virus that belongs to the genus hepacivirus of the Flaviviridae family. Six major HCV genotypes (1–6) are known, each of which can be further subdivided into several subtypes (1a, 1b, 2a, etc). The HCV genome consists of a large open reading frame (ORF), flanked by highly structured 5’ and 3’ untranslated regions (UTRs). Both UTRs are conserved and control viral translation and replication. The HCV 5'-UTR contains an IRES that initiates cap-independent translation of the viral RNA. IRES-mediated translation of the HCV ORF yields a single polyprotein precursor that is co- and post-translationally processed by cellular and viral proteases, giving rise to mature structural and non structural proteins. Several studies have suggested that different cellular non canonical proteins or viral proteins can regulate the HCV IRES activity. The aim of this study was to understand the regulation of the HCV IRES dependent translation. Firstly, we tried to delineate the role of the viral proteins on HCV IRES dependent translation that still remains controversial. Clearly our studies demonstrated that HCV NS5A down-regulates IRES activity in a cell-type dependent manner. Additionally, we provide strong evidence that activated PKR up-regulates the IRES activity while silencing of endogenous PKR had the opposite effect. In addition, we concluded that the NS5A-mediated inhibitory effect on IRES-dependent translation was linked with the PKR inactivation. Moreover, as it is already reported that localised hypoxic areas are continuously present in HCC due to its high proliferation rate leading to an altered translation pattern, we investigated modulation of HCV IRES activity under low oxygen settings. Our results provided preliminary evidence that HCV-IRES-dependent translation is negatively regulated by low oxygen levels or under hypoxia-mimicking conditions in cell-specific manner.

H λοίμωξη που προκαλείται απο τον ιό της ηπατίτιδας C HCV είναι μείζον πρόβλημα για την δημόσια υγεία όπως επίσης και η κύρια αιτία της χρόνιας ηπατικής νόσου και ηπατοκυτταρικού καρκινώματος, με περίπου 180 εκατομμύρια μολυσμένα άτομα σε όλο τον κόσμο. Ο HCV είναι ένας RNA ιός θετικής πολικότητας που ανήκει στο γένος Hepacivirus της οικογένειας των Flaviviridae. Έξι γονότυποι ( 1-6 ) είναι γνωστοί, καθένας από τους οποίους μπορεί να υποδιαιρεθεί περαιτέρω σε αρκετές υποτύπους. Το γονιδίωμα του HCV αποτελείται από ένα μεγάλο ανοικτό πλαίσιο ανάγνωσης (ORF), πλαισιωμένο από ιδιαίτερα δομημένες 5 'και 3' αμετάφραστες περιοχές (UTRs). Και οι δύο περιοχές UTRs είναι συντηρημένες και έχουν τον έλεγχο της ιογενούς μετάφρασης και αναπαραγωγής. Το 5' UTR του HCV περιέχει μια περιοχή IRES απο την οποία γινεται η έναρξη της cap ανεξάρτητης μετάφρασης του ιικού RNA. Η HCV IRES εξαρτώμενη μετάφραση του ORF παράγει μια ενιαία πρόδρομη…

Subjects/Keywords: Ηπατίτιδα C, Ιός (HCV); Hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Karamichali, E. (2014). Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. (Thesis). University of Patras; Πανεπιστήμιο Πατρών. Retrieved from http://hdl.handle.net/10442/hedi/35595

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Karamichali, Eirini. “Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.” 2014. Thesis, University of Patras; Πανεπιστήμιο Πατρών. Accessed March 02, 2021. http://hdl.handle.net/10442/hedi/35595.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Karamichali, Eirini. “Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C.” 2014. Web. 02 Mar 2021.

Vancouver:

Karamichali E. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. [Internet] [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2014. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/10442/hedi/35595.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Karamichali E. Ρύθμιση της έκφρασης του IRES (εσωτερική θέση πρόσβασης του ριβοσώματος) του ιού της ηπατίτιδας C. [Thesis]. University of Patras; Πανεπιστήμιο Πατρών; 2014. Available from: http://hdl.handle.net/10442/hedi/35595

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Ryerson University

20. Zalai, Dora, Marta. Fatigue in chronic hepatitis C infection a mixed method study.

Degree: 2014, Ryerson University

URL: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

► Fatigue is a main patient reported outcome of chronic hepatitis C (HCV) infection; yet its contributors are unknown. Objectives: The study (1) evaluated fatigue predictors,… (more)

Subjects/Keywords: Hepatitis C.; Hepatitis C virus.; Fatigue; Sleep disorders

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zalai, Dora, M. (2014). Fatigue in chronic hepatitis C infection a mixed method study. (Thesis). Ryerson University. Retrieved from https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zalai, Dora, Marta. “Fatigue in chronic hepatitis C infection a mixed method study.” 2014. Thesis, Ryerson University. Accessed March 02, 2021. https://digital.library.ryerson.ca/islandora/object/RULA%3A2995.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zalai, Dora, Marta. “Fatigue in chronic hepatitis C infection a mixed method study.” 2014. Web. 02 Mar 2021.

Vancouver:

Zalai, Dora M. Fatigue in chronic hepatitis C infection a mixed method study. [Internet] [Thesis]. Ryerson University; 2014. [cited 2021 Mar 02]. Available from: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zalai, Dora M. Fatigue in chronic hepatitis C infection a mixed method study. [Thesis]. Ryerson University; 2014. Available from: https://digital.library.ryerson.ca/islandora/object/RULA%3A2995

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

21. Grandal Fustes, Marta. Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa .

Degree: 2019, Universidad da Coruña

URL: http://hdl.handle.net/2183/24358

► [Resumen] La infección por el Virus de la Hepatitis C (VHC) es un problema grave de salud pública mundial, que actualmente afecta a más de… (more)

▼ [Resumen] La infección por el Virus de la Hepatitis C (VHC) es un problema grave de salud pública mundial, que actualmente afecta a más de 71 millones de personas en todo el mundo, y que lidera una significativa morbilidad y mortalidad. Desde la aprobación de los nuevos antivirales de acción directa (AADs), el paradigma de la infección por VHC ha cambiado. Los regímenes con AADs son ahora el nuevo estándar de tratamiento frente al VHC con tasas de respuesta virológica sostenida (RVS) de más del 90%, de corta duración y sin apenas efectos adversos asociados. Sin embargo, en un primer momento, sus elevados costes supusieron una limitación para ofrecer un tratamiento global a los pacientes con infección por VHC. Esta situación fue resuelta en mayo de 2015 cuando el Sistema Nacional de Salud (SNS) español publicó el Plan Estratégico para el Abordaje de la Hepatitis C (PEAHC) que establecía los criterios para la priorización del tratamiento con los nuevos AADs. A pesar de las altas tasas de curación asociadas a los nuevos AADs superiores al 90%, existe todavía una proporción de pacientes entre un 2-10% que no alcanza una RVS. Entre las diferentes causas asociadas a esta falta de respuesta están numerosos factores como el grado de fibrosis hepática, la exposición previa a terapias con IFN, la carga viral, el genotipo viral o la presencia de mutaciones de resistencia (RASs) en regiones del genoma viral que son las dianas terapéuticas de los AADs (como NS5A). Además, las RASs generalmente se asocian a fracaso terapéutico cuando su presencia se combina con algunos de los demás factores relacionados con menores tasas de RVS. Todos estos factores han de tenerse en cuenta para optimizar la elección de tratamiento y su duración, con el fin de asegurar la mejor respuesta posible. En este contexto, los objetivos de este trabajo fueron, en primer lugar, caracterizar el perfil de la infección crónica por VHC en el área sanitaria de A Coruña, y evaluar el impacto del PEAHC en el abordaje del tratamiento de la infección en esta población. En segundo lugar, los objetivos fueron evaluar la prevalencia de RASs basales en NS5A en pacientes con genotipo 1a (G1a) y genotipo 3 (G3), y evaluar los beneficios de la realización de un estudio de resistencias para optimizar las estrategias terapéuticas disponibles. Los resultados obtenidos en el primer estudio, señalaron que el perfil de la infección crónica por VHC en el área sanitaria de A Coruña se caracterizaba por una prevalencia mayoritaria en varones (76,2%) con una media de edad de 50 ± 9,5 años, donde la cirrosis hepática (28,7%) y la co-infección por VIH (60,9%) fueron frecuentes. A nivel virológico, el virus presentó cargas virales elevadas y el genotipo mayoritario fue el 1 (66,1%), subtipo 1a (41,5%), seguido del G3 (16,8%). Durante el año 2015 el 52,7% de los pacientes iniciaron tratamiento con una tasa de RVS global superior al 96%. No se observaron diferencias significativas entre esta RVS y factores relacionados con peor respuesta al tratamiento… Advisors/Committee Members: Poveda, Eva (advisor), Pedreira Andrade, José Domingo (advisor).

Subjects/Keywords: Virus de la hepatitis C; Hepatitis C-Tratamiento; Antivirales-Investigación

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Grandal Fustes, M. (2019). Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa . (Doctoral Dissertation). Universidad da Coruña. Retrieved from http://hdl.handle.net/2183/24358

Chicago Manual of Style (16^th Edition):

Grandal Fustes, Marta. “Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa .” 2019. Doctoral Dissertation, Universidad da Coruña. Accessed March 02, 2021. http://hdl.handle.net/2183/24358.

MLA Handbook (7^th Edition):

Grandal Fustes, Marta. “Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa .” 2019. Web. 02 Mar 2021.

Vancouver:

Grandal Fustes M. Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa . [Internet] [Doctoral dissertation]. Universidad da Coruña; 2019. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/2183/24358.

Council of Science Editors:

Grandal Fustes M. Caracterización epidemiológica y virológica en pacientes con infección crónica por el Virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa . [Doctoral Dissertation]. Universidad da Coruña; 2019. Available from: http://hdl.handle.net/2183/24358

University of KwaZulu-Natal

22. Shunmugam, Letitia. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

Degree: 2019, University of KwaZulu-Natal

URL: https://researchspace.ukzn.ac.za/handle/10413/16623

► Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive intervention to alleviate its control. Over the years, drug design… (more)

▼ Hepatitis C Virus (HCV) is an escalating global healthcare and economic burden that requires extensive intervention to alleviate its control. Over the years, drug design efforts have produced many anti-HCV drugs; however, due to drug resistance brought on by numerous genetic variations of the virus and lack of specificity and stability, current drugs are rendered ineffective. The situation has been further intensified by the absence of a viable vaccine. For these reasons, continuous HCV research is imperative for the design and development of promising inhibitors that address the challenges faced by present antiviral therapies. Moreover, exposure of previously neglected viral protein targets can offer another potentially valuable therapeutic route in drug design research. Structure-based drug design approaches accentuate the development of small inhibitor molecules that interact with therapeutic targets through non-covalent interactions. The unexpected discovery of covalent inhibitors and their distinctive nature of instigating complete and irreversible inhibition of targets have shifted attention away from the use of non-covalent drugs in antiviral treatment. This has led to significant progress in understanding covalent inhibition regarding their underlying mechanism of action and in the design of novel covalent inhibitors that work against biological targets. However, due to difficulties arising in its application and resultant safety, the pharmaceutical industry were reluctant to pursue this strategy. With the use of rational drug design, a novel strategy was then proposed known as selective covalent inhibition. Due to the lack of competent protocols and information, little is known regarding selective covalent inhibition This study investigates three biological HCV targets, NS3 protease, RNA helicase and NS5B RNAdependent RNA polymerase. With constantly evolving viruses like HCV, computational methods including molecular modelling and docking, virtual screening and molecular dynamic simulations have allowed chemists to screen millions of compounds to filter out potential lead drugs. These in silico approaches have allowed Computer-Aided Drug Design as a cost-effective strategy to accelerate the process of drug discovery. The above techniques, with numerous other computational tools were employed in this study to fill the gap in HCV drug research by providing insights into the structural and dynamic changes that describe the mechanism of selective covalent inhibition and pharmacophoric features that lead to unearthing of potential small inhibitor molecules against Hepatitis C. v The first study (Chapter 4) provides a comprehensive review on HCV NS3/4A protein, current therapies and covalent inhibition as well as introduces a technical guideline that provides a systematic approach for the design and development of potent, selective HCV inhibitors. The second study (Chapter 5) provides a comprehensive understanding concerning the implications of selective covalent inhibition on the… Advisors/Committee Members: Soliman, Mahmoud Elsayed Soliman. (advisor).

Subjects/Keywords: Hepatitis C virus - drug design.; Hepatitis C virus - drug delivery.

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Shunmugam, L. (2019). In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. (Thesis). University of KwaZulu-Natal. Retrieved from https://researchspace.ukzn.ac.za/handle/10413/16623

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Shunmugam, Letitia. “In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.” 2019. Thesis, University of KwaZulu-Natal. Accessed March 02, 2021. https://researchspace.ukzn.ac.za/handle/10413/16623.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Shunmugam, Letitia. “In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.” 2019. Web. 02 Mar 2021.

Vancouver:

Shunmugam L. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. [Internet] [Thesis]. University of KwaZulu-Natal; 2019. [cited 2021 Mar 02]. Available from: https://researchspace.ukzn.ac.za/handle/10413/16623.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Shunmugam L. In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase. [Thesis]. University of KwaZulu-Natal; 2019. Available from: https://researchspace.ukzn.ac.za/handle/10413/16623

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

23. Margusino Framiñán, Luis. Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales .

Degree: 2020, Universidad da Coruña

URL: http://hdl.handle.net/2183/26574

► [Resumen] El virus de la hepatitis C (VHC) es un virus ácido ribonucleico (ARN) monocatenario identificado como el agente etiológico de la hepatitis C. El… (more)

▼ [Resumen] El virus de la hepatitis C (VHC) es un virus ácido ribonucleico (ARN) monocatenario identificado como el agente etiológico de la hepatitis C. El principal órgano diana del VHC es el hígado, donde puede desarrollar una hepatitis aguda y/o crónica que, a largo plazo, puede causar fibrosis hepática, cirrosis hepática, carcinoma hepatocelular (CHC) y, finalmente, la muerte. Se han aislado 6 genotipos principales del VHC, con desigual distribución a nivel mundial y un séptimo genotipo en algunos individuos. Esta heterogeneidad genética tiene importantes implicaciones a nivel de la evolución de la enfermedad hepática del paciente infectado y en la selección y efectividad del tratamiento antiviral en práctica clínica. Particularmente, la infección crónica por el genotipo 3 del VHC tiene una progresión más rápida en todos los estadios de la enfermedad hepática y peor respuesta a los tratamientos antivirales disponibles. El objetivo del tratamiento antiviral frente al VHC es curar la infección por este virus para prevenir las complicaciones hepáticas y enfermedades extrahepáticas relacionadas (necroinflamación hepática, fibrosis, cirrosis, descompensación de cirrosis, CHC, manifestaciones graves extrahepáticas y muerte), mejorar la calidad de vida, eliminar el estigma y evitar la transmisión posterior del VHC. Según las sociedades científicas de referencia en nuestro ámbito, todos los pacientes con una hepatitis C crónica (HCC), monoinfectados o coinfectados con el virus de la inmunodeficiencia humana adquirida (VIH), naïve o previamente tratados con fallo terapéutico, y sin contraindicaciones para el tratamiento, deben ser considerados candidatos a tratamiento antiviral, independientemente de su grado de fibrosis. El tratamiento de la infección crónica por VHC ha experimentado una evolución muy importante, especialmente en las últimas dos décadas, conforme se han autorizado nuevos medicamentos más eficaces y seguros frente a este virus. Los resultados de los ensayos clínicos han posicionado muy recientemente a los antivirales de acción directa (AAD) como los medicamentos de elección en el tratamiento de la infección crónica por VHC. Existen tres amplias clases de antivirales de acción directa que actúan a distintos niveles del ciclo biológico del VHC: inhibidores de proteasa NS3/4A, inhibidores del complejo de replicación NS5A e inhibidores de la polimerasa NS5B, que se dividen en inhibidores de nucleos(t)idos o inhibidores no nucleósidos. La selección del tratamiento antiviral es independiente de la coinfección por VIH y depende básicamente de tres variables: genotipo/subtipo de VHC, gravedad de enfermedad hepática y/o tratamientos previos. Otras variables dependientes del virus, del paciente o del tratamiento basal de paciente podrían condicionar el resultado del tratamiento antiviral frente al virus de la hepatitis C en la práctica clínica. Por lo tanto, es importante conocer la efectividad y seguridad en práctica clínica real de los antivirales de acción directa en pacientes diagnosticados de hepatitis C… Advisors/Committee Members: Castro-Iglesias, Ángeles (advisor).

Subjects/Keywords: Antivirales-Investigación; Hepatitis C-Tratamiento; Virus de la hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Margusino Framiñán, L. (2020). Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales . (Doctoral Dissertation). Universidad da Coruña. Retrieved from http://hdl.handle.net/2183/26574

Chicago Manual of Style (16^th Edition):

Margusino Framiñán, Luis. “Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales .” 2020. Doctoral Dissertation, Universidad da Coruña. Accessed March 02, 2021. http://hdl.handle.net/2183/26574.

MLA Handbook (7^th Edition):

Margusino Framiñán, Luis. “Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales .” 2020. Web. 02 Mar 2021.

Vancouver:

Margusino Framiñán L. Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales . [Internet] [Doctoral dissertation]. Universidad da Coruña; 2020. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/2183/26574.

Council of Science Editors:

Margusino Framiñán L. Efectividad y seguridad de los antivirales de acción directa frente al virus de la hepatitis C: foco en subpoblaciones especiales . [Doctoral Dissertation]. Universidad da Coruña; 2020. Available from: http://hdl.handle.net/2183/26574

24. Villegas Chiroque, Miguel. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.

Degree: 2013, National University of San Marcos

URL: http://hdl.handle.net/20.500.12672/3409

► – We performed a retrospective study of cases and controls to assess predictors of efficacy of combination therapy with pegylated interferon alpha (Peg IFN-) and… (more)

Subjects/Keywords: Hepatitis C - Tratamiento; Virus de la hepatitis C

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Villegas Chiroque, M. (2013). Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. (Thesis). National University of San Marcos. Retrieved from http://hdl.handle.net/20.500.12672/3409

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Villegas Chiroque, Miguel. “Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.” 2013. Thesis, National University of San Marcos. Accessed March 02, 2021. http://hdl.handle.net/20.500.12672/3409.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Villegas Chiroque, Miguel. “Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011.” 2013. Web. 02 Mar 2021.

Vancouver:

Villegas Chiroque M. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. [Internet] [Thesis]. National University of San Marcos; 2013. [cited 2021 Mar 02]. Available from: http://hdl.handle.net/20.500.12672/3409.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Villegas Chiroque M. Factores predictivos de respuesta al tratamiento contra la hepatitis C crónica en pacientes atendidos en el Hospital Militar Central Lima Perú, 2006-2011. [Thesis]. National University of San Marcos; 2013. Available from: http://hdl.handle.net/20.500.12672/3409

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Indian Institute of Science

25. Bose, Mihika. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.

Degree: PhD, Faculty of Science, 2017, Indian Institute of Science

URL: http://etd.iisc.ac.in/handle/2005/2920

► Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million… (more)

▼ Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million people worldwide. About 70% of infected individuals fail to clear the virus and subsequently develop chronic hepatitis, frequently leading to liver cirrhosis and in some cases hepatocellular carcinoma. Therapeutic options for HCV infection are still limited and a protective vaccine is not yet available. Currently available therapies include administration of pegylated alpha interferon in combination with ribavirin. The recently approved protease inhibitors Boceprevir and Telaprevir are also included in the treatment regimen. However, limitations to the treatment with direct-acting antivirals (DAAs) are associated with severe side effects and low sustained virological response (SVR) rates that vary depending on the virus and host genotype. The replication step of the viral life cycle is mostly targeted by majority of DAAs. Recent findings have suggested that a combination of entry inhibitors together with DAAs exhibit a synergistic effect in the treatment of HCV. Therefore, identification of efficient HCV entry inhibitors is of high priority In vitro studies have shown that HCV attachment and subsequent entry into the host cells is mediated by E1 and E2 viral envelope proteins. HCV entry requires interaction with a number of receptors which include CD81, scavenger receptor B1 (SR-B1) and the tight junction proteins, claudin 1 (CLDN1) and occludin (OCLN). Since the E2 glycoprotein is reported to interact directly with cellular receptors, it is an attractive target for neutralisation. The present study focuses on the establishment and characterisation of entry inhibitors as antivirals for HCV. The thesis is presented in three chapters: Chapter 1- ‘Introduction’, provides a brief overview on HCV genotypes, genome organisation, life cycle including details on the entry process and therapies used for the treatment of HCV. Chapter 2 describes the generation of monoclonal antibodies (mAbs) against HCV envelope proteins as potent anti-viral agents for the prevention of HCV infection. Data on the identification and characterization of the neutralizing epitopes of HCV envelope proteins have been presented. Chapter 3 includes isolation of entry inhibitors of HCV from natural sources and identification and characterization of the active components exhibiting antiviral property. A number of studies have reported the role of neutralizing antibodies in the course of HCV infection and emerging data suggest protective effect of antibodies against HCV infection. Most of the ongoing studies are based on HCV genotype 1a which is prevalent globally. However in India, the prevalent genotype is 3a. Therefore, we established a panel of mAbs against HCV-LPs comprising of core-E1-E2 derived from genotype 3a as described in chapter 2. HCV-LP based system has been used in this study since it mimics the biophysical conformation, morphology and antigenic properties of the native… Advisors/Committee Members: Karande, Anjali A (advisor).

Subjects/Keywords: Hepatitis C Virus; Monoclonal Antibodies; Hepatitis C Virus Infection; Hepatitis C Virus Entry; HCV Small Molecule Inhibitors; Hepatitis C Virus Treatment; HCV Treatment; Rutin; Hepatitis C Virus E2 Protein; Biochemistry

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Bose, M. (2017). Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. (Doctoral Dissertation). Indian Institute of Science. Retrieved from http://etd.iisc.ac.in/handle/2005/2920

Chicago Manual of Style (16^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2017. Doctoral Dissertation, Indian Institute of Science. Accessed March 02, 2021. http://etd.iisc.ac.in/handle/2005/2920.

MLA Handbook (7^th Edition):

Bose, Mihika. “Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors.” 2017. Web. 02 Mar 2021.

Vancouver:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Internet] [Doctoral dissertation]. Indian Institute of Science; 2017. [cited 2021 Mar 02]. Available from: http://etd.iisc.ac.in/handle/2005/2920.

Council of Science Editors:

Bose M. Characterisation of Monoclonal Antibodies and Small Molecule Inhibitors as Hepatitis C Virus Entry Inhibitors. [Doctoral Dissertation]. Indian Institute of Science; 2017. Available from: http://etd.iisc.ac.in/handle/2005/2920

26. Dakić Zoran. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.

Degree: 2017, University of Novi Sad

URL: https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; https://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

►

Adekvatni nadzor nad zaraznim bolestima predstavlja aktuelni izazov ne samo kod nas već i u razvijenim zemljama. Savremeni epidemiološki nadzor nad zaraznim bolestima zasniva… (more)

▼

Adekvatni nadzor nad zaraznim bolestima predstavlja aktuelni izazov ne samo kod nas već i u razvijenim zemljama. Savremeni epidemiološki nadzor nad zaraznim bolestima zasniva se na odgovarajućim definicijama slučaja. Njihova osnovna funkcija je olakšavanje prepoznavanja određenih bolesti i njihovo registrovanje na jednoobrazan način. Definisanje slučajeva zaraznih bolesti nije jednostavno, jer uključuje kliničke, epidemiološke i laboratorijske parametre, uz istovremeno očekivanje visoke senzitivnosti i specifičnosti. Ciljevi istraživanja su bili da se utvrdi primenljivost definicija slučaja hepatitisa B i C na Klinici za infektivne bolesti Kliničkog centra Vojvodine, te da se utvrdi senzitivnost i specifičnost primenjenih definicija slučaja hepatitisa B i C. Uz postojeći dijagnostički algoritam Klinike za infektivne bolesti Kliničkog centra Vojvodine, uvedena su tri seta definicija hepatitisa B i C: Evropskog centra za prevenciju i kontrolu bolesti (ECDC) iz 2008. i 2012.godine kao i američkih Centara za kontrolu bolesti (CDC) iz 2012. godine. Istraživanje je sprovedeno na Klinici za infektivne bolesti Kliničkog centra Vojvodine i tokom 12 meseci, u skladu sa predloženim definicijama slučaja, identifikovano je 150 ispitanika obolelih od hepatitisa B i C. Utvrđene su sledeće činjenice: preporučene definicije slučaja su primenljive u Republici Srbiji za laboratorijske i kliničke kriterijume, dok uključivanje epidemiološke povezanosti u definicije slučaja ima malo praktičnog značaja za prijavljivanje hepatitisa; definicije slučaja koje uključuju i obavezno prisustvo kliničkih kriterijuma (najčešće definicije verovatnog slučaja) imaju nisku senzitivnost, a visoku specifičnost, kao posledica prisustva infekcije i u odsustvu bilo kakvih kliničkih manifestacija; definicije slučaja koje se zasnivaju samo na laboratorijskim kriterijumima imaju maksimalnu senzitivnost i specifičnost.

Adequate surveillance of communicable diseases is the actual challenge, not only in our country but also in developed countries. Modern epidemiological surveillance of communicable diseases is based on the appropriate case definitions. Their main purpose of them is to facilitate the recognition of certain diseases and their registration in a uniform manner. Case definition of communicable diseases is not easy, because it involves clinical, epidemiological and laboratory parameters, along with the expectated high sensitivity and specificity.The objectives of the study were to determine the applicability of the casedefinitions for hepatitis B and C in the Clinic for Infectious Diseases of the Clinical Center of Vojvodina and to determine the sensitivity and specificity of the applied definition of cases of hepatitis B and C. In addition to existing diagnostic algorithm of the Clinic for Infectious Diseases, three sets of hepatitis B and C case definitions were introduced: the European Centre for Disease Prevention and Control in 2008 and 2012 as well as the US Centers for Disease Control in 2012. The…

Advisors/Committee Members: Đurić Predrag, Fabri Milotka, Dragovac Gorana, Kocić Biljana, Turkulov Vesna, Dugandžija Tihomir, Petrović Vladimir.

Subjects/Keywords: hepatitis B; hepatitis C; dijagnoza; epidemiologija; javno zdravlje; Hepatitis B; Hepatitis C; Diagnosis; Epidemiology; Public Health

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zoran, D. (2017). Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. (Thesis). University of Novi Sad. Retrieved from https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; https://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zoran, Dakić. “Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.” 2017. Thesis, University of Novi Sad. Accessed March 02, 2021. https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; https://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zoran, Dakić. “Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C.” 2017. Web. 02 Mar 2021.

Vancouver:

Zoran D. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. [Internet] [Thesis]. University of Novi Sad; 2017. [cited 2021 Mar 02]. Available from: https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; https://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zoran D. Značaj primene definicije slučaja za unapređenje epidemiološkog nadzora nad hepatitisima B i C. [Thesis]. University of Novi Sad; 2017. Available from: https://www.cris.uns.ac.rs/DownloadFileServlet/Disertacija145923723116719.pdf?controlNumber=(BISIS)100362&fileName=145923723116719.pdf&id=5188&source=OATD&language=en ; https://www.cris.uns.ac.rs/record.jsf?recordId=100362&source=OATD&language=en

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

NSYSU

27. Tsai, Kai-yang. The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study.

Degree: Master, Computer Science and Engineering, 2015, NSYSU

URL: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0517115-215120

► Liver cancer, mostly arising from hepatitis type A, B, C, D, and E, constitutes about 10% of total death in Taiwan. Among them, hepatitis B… (more)

▼ Liver cancer, mostly arising from hepatitis type A, B, C, D, and E, constitutes about 10% of total death in Taiwan. Among them, hepatitis B and C are regarded as the main culprits leading to liver cancer. The subsequent development after infecting hepatitis B or C has drawn scholarsâ attention. Studies that analyze the relation between hepatitis B viral (HBV) and cancers flourish in academic field [1-10]. HBV is the risk factor for Hepatocellular Carcinoma (HCC) and accounts for at least 50% cases of HCC [1-3]. Recently the correlation between hepatitis viral infection and the occurrence of pancreatic cancer was also studied. Patients with HBV will have an increased risk of infecting pancreatic cancer according to studies conducted by China [4,5]. However, no significant relation was found in a reported by Taiwanese scholars [10]. The follow-up researches exploring the relevance of HBV infection to lymphoma were performed in many different countries. Italian scholar reported patients with B cell lymphoma have higher viral infection rate of hepatitis C [6]. On the other hand, researches performed in France, Germany and US revealed that such a relationship does not exist [6-9]. This indicates that the relation between hepatitis and cancer occurrence might be pending on factors relating to region or species. Even though the correlation between the infection of HBV and liver cancer was confirmed, yet relatively few researches targeting on the relation of HBV and the incidence of cancers other than liver cancer were reported. This study aims at evaluating the effect of HBV infection on cancers in Taiwan by analyzing data retrieved from National Health Insurance Research Database (NHIRD) from January 1996 to December 2010. A nationwide HBV cohort prospective study to investigate whether HBV increases the risks of cancers and cancers incidence in Taiwan. With the information provided by this research, the treatment and prognosis following can be properly planned and predicted. Advisors/Committee Members: Tan-Hsu Tan (chair), Chungnan Lee (chair), Wen-Hsien Ho (chair), John Y. Chiang (committee member).

Subjects/Keywords: Cancer; Hepatitis C; National Health Insurance Research Database (NHIRS); Hepatitis B

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tsai, K. (2015). The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study. (Thesis). NSYSU. Retrieved from http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0517115-215120

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Tsai, Kai-yang. “The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study.” 2015. Thesis, NSYSU. Accessed March 02, 2021. http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0517115-215120.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Tsai, Kai-yang. “The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study.” 2015. Web. 02 Mar 2021.

Vancouver:

Tsai K. The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study. [Internet] [Thesis]. NSYSU; 2015. [cited 2021 Mar 02]. Available from: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0517115-215120.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Tsai K. The association of Hepatitis B viral infection with the occurrence of cancers: A nationwide population-based cohort study. [Thesis]. NSYSU; 2015. Available from: http://etd.lib.nsysu.edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0517115-215120

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

28. Celina Maria Pereira de Moraes Soares. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.

Degree: 2006, Universidade Católica de Santos

URL: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

► Esta pesquisa é um estudo transversal, com método quantitativo e análise de prevalência dos dados. Apresenta como objetivo estimar a soroprevalência das hepatites virais B… (more)

▼ Esta pesquisa é um estudo transversal, com método quantitativo e análise de prevalência dos dados. Apresenta como objetivo estimar a soroprevalência das hepatites virais B e C em pacientes infectados pelo HIV. A justificativa deste estudo evidencia-se nas atuais doenças sexualmente transmissíveis (HIV e HBV) e de transmissão sanguínea (HIV, HBV e HCV), por protagonizar substancialmente o panorama do enfrentamento mundial em saúde pública. Santos/SP, cidade litorânea e turística, onde está localizado o maior porto marítimo da América Latina, com um grande número de homens que fazem sexo com homens, mulheres trabalhadores do sexo e usuários de drogas injetáveis, além de apresentar população flutuante de turistas, trabalhadores diretos e indiretos na atividade portuária. Neste sentido constrói um perfil humano relevante que caracteriza a elaboração do atual estudo. A coleta de dados foi realizada na população de pacientes matriculados no Centro de Referência em Aids CRAIDS, Santos, SP. A amostra foi constituída por 1438 pessoas, no período de fevereiro de 2004 a fevereiro de 2005. A análise nos prontuários foi realizada selecionando resultados de marcadores sorológicos para as hepatite B (HBsAg e anti-HBs) e hepatite C (anti-HCV), pela técnica de ELISA, além dos exames sorológicos de menor contagem de linfócitos T CD4+ e maior contagem de carga viral para o HIV, considerando as variáveis: sexo, idade, escolaridade, estado civil, forma de contaminação. Os resultados demonstraram que na população dos 1438 indivíduos HIV+, 54.6% eram do sexo masculino e 45.4% do feminino. Em relação à idade, 71% estavam entre 30 e 49 anos e 54.3% com nível de escolaridade no ensino fundamental. A contagem de linfócitos CD4+ revelou 43.7% com níveis abaixo de 200 células /mm. Considerando a soroprevalência dos marcadores HBsAg, anti-HBs, Anti-HCV e fatores de risco para essas doenças obtivemos uma prevalência global de HBsAg de 7.4% e 23.5% para o anti-HCV. As variáveis que apresentaram associação com o HBV foram: idade, baixos níveis de células T CD4+, homossexualidade masculina e UDI; para HCV: idade, sexo, escolaridade de nível superior e UDI. Advisors/Committee Members: Marcos Montani Caseiro.

Subjects/Keywords: soroprevalência; hepatitis B; hepatitis C; HIV; fatores de risco; SAUDE COLETIVA

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Soares, C. M. P. d. M. (2006). Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. (Thesis). Universidade Católica de Santos. Retrieved from http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Soares, Celina Maria Pereira de Moraes. “Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.” 2006. Thesis, Universidade Católica de Santos. Accessed March 02, 2021. http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Soares, Celina Maria Pereira de Moraes. “Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005.” 2006. Web. 02 Mar 2021.

Vancouver:

Soares CMPdM. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. [Internet] [Thesis]. Universidade Católica de Santos; 2006. [cited 2021 Mar 02]. Available from: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Soares CMPdM. Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005. [Thesis]. Universidade Católica de Santos; 2006. Available from: http://biblioteca.unisantos.br/tede/tde_busca/arquivo.php?codArquivo=4

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Addis Ababa University

29. BAYE, GELAW. THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA .

Degree: 2008, Addis Ababa University

URL: http://etd.aau.edu.et/dspace/handle/123456789/2942

► Blood has long been recognized as a vehicle for transmission of infectious organisms, including viruses, bacteria, and parasites. The most important ones are HIV-1 and… (more)

▼ Blood has long been recognized as a vehicle for transmission of infectious organisms, including viruses, bacteria, and parasites. The most important ones are HIV-1 and 2, HBV, HCV, and malaria parasites. Determination of the prevalence of HBV, HCV and malaria parasites in a population in general, and blood donor in particular will certainly help in making health policy decisions. The primary aim of this study was to demonstrate the prevalence of HBV, HCV, and malaria parasites among healthy adult blood donors in Gondar, Bahirdar, Dessie and Mekele blood banks. Socio-demographic characteristics of the blood donors and the history of hepatitis virus infection, history of malaria infection together with the number of sexual partners in life and history of repeated donation was assessed by questionnaire. Of the blood donors 578 were males and 22 females. The age distribution ranges from 18 to 69 years and the maximum (59.5%) blood donation age category was between 19 to 28 years of age. Serum samples from 600 blood donors, 300 from Gondar and 100 each from the three study areas (Bahirdar, Dessie, and Mekele) were collected from December 2002 to February 2003. The over all prevalences of HBsAg, HCV and malaria parasites were 6.2%, 1.7% and 1% respectively. All hepatitis virus positive blood donors were males. The prevalence of HBsAg in age category 19 to 28 years was 62.2% (23/37) followed by age category 29 to 38 years (24.3%). Fifty percent (5/10) of HCV positive blood donors was in age category between 19 to 28 years. Single blood donors were more positive than the married ones (OR=1.9; 95%CI 0.8-4.6). In this study all positive blood donors for HBsAg and anti-HCV were not having the history of hepatitis virus infection and repeated blood donation was not found to be a risk factor for HBsAg and anti-HCV positivity (p=0.7 and p=0.8, respectively). Three hundred one blood donors were without sexual partners and 252 with only one sexual partner in life. Among the positives for HBsAg and HCV antibody, 59.5% and 20% respectively were with single sexual partner. The prevalence of HBsAg, and anti- HCV found by this study are quite important. Therefore, screening blood donors for both HBV and HCV infection is indispensable for safe blood transfusion. The limitations of the majority of serological tests in general, and the ACON test strip kit in particular are also considerable especially for anti-HCV determination during the window period. Asking blood donors for recent malaria infection and confirming negativity by viii laboratory tests need to be included in daily donor selection. Hepatitis B surface antigen detection may not rule out the over all prevalence of the disease. Therefore, determination of other markers including anti-HBS, anti- HBe, anti-HBC together with HCV antigen are being recommended in the future to assure safe blood donation. Advisors/Committee Members: Yohannes Mengistu (PhD) (advisor).

Subjects/Keywords: Hepatitis B virus; Hepatitis C virus; blood donor; malaria parasites; prevalence

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

BAYE, G. (2008). THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA . (Thesis). Addis Ababa University. Retrieved from http://etd.aau.edu.et/dspace/handle/123456789/2942

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

BAYE, GELAW. “THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA .” 2008. Thesis, Addis Ababa University. Accessed March 02, 2021. http://etd.aau.edu.et/dspace/handle/123456789/2942.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

BAYE, GELAW. “THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA .” 2008. Web. 02 Mar 2021.

Vancouver:

BAYE G. THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA . [Internet] [Thesis]. Addis Ababa University; 2008. [cited 2021 Mar 02]. Available from: http://etd.aau.edu.et/dspace/handle/123456789/2942.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

BAYE G. THE PREVALENCE OF HBV, HCV AND MALARIA PARASITES IN BLOOD DONORS IN AMHARA AND TIGRAY NATIONAL STATES, ETHIOPIA . [Thesis]. Addis Ababa University; 2008. Available from: http://etd.aau.edu.et/dspace/handle/123456789/2942

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Addis Ababa University

30. Jijiga, Edosa. Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia.

Degree: 2014, Addis Ababa University

URL: http://etd.aau.edu.et/dspace/handle/123456789/5846

► Abstract Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and syphilis are the most serious infections transmitted during blood transfusion.… (more)

▼ Abstract Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and syphilis are the most serious infections transmitted during blood transfusion. In such a resource limited setting, cheaper and feasible alternative strategies for blood donations testing are speciﬁcally required. However, updated data on the transfusion transmissible infections (TTIs), and cost effective strategies of blood screening are lacking. Objective: To determine the prevalence of transfusion transmissible infections among blood donorsfrom July 2008 to July 2013and propose cost effective strategy of blood screening at National Blood Bank of Addis Ababa, Ethiopia. Methodology:A retrospective analysis of blood donors’ record covering the period from July 2008 to July 2013 was conducted. The data was collected from the National Blood Transfusion Services (NBTS) of Addis Ababa and includes category of all donors and result for TTI markers. In addition, direct laboratory costs of parallel versus sequential strategy of blood screening were compared. To compare the strategies we used the current price of the laboratory costs. Data was first exported to Excel spread sheet from the institution’s data base and then finally exported to SPSS version 16 software (SPSS INC, Chicago, IL, USA) for analysis.Data analysis was performed using scores and odds ratio using same software to look for an association between dependent and independent variables. P values less than 0.05 were considered significant. Result: A total of 173,207 consecutive blood donors were screened between 2008 and 2013.The overall seroprevalence rate ofHBV, HIV, HCV and syphilis of blood donors was 5.0%, 1.6%, 1.4% and 0.1%respectively. The HIV-HBV confection was higher among blood donors 135(41.79%) followed by HBV-HCV co-infection which accounts about 103(31.89%). Significantly increased seroprevalence of TTI’s was observed in the age groups of 17-25 and 2635 years. In this study, the difference in cost between the current in use strategy (Parallel) versus our proposed newly designed sequential testing algorithm was 746,773.90 ETB. Conclusion: A significant percentage of the blood donors harbor TTIs. Higher prevalence of TTIs was observed among youths and replacement donors. The direct laboratory cost analysis using current in use strategy (parallel) was higher than the newly designed sequential testing algorithm. Thus, the new strategy can be implemented to make screening of TTIs cost effective in the face of the current effort of large mobilization of voluntary blood donors in the country. Advisors/Committee Members: Aster Tsegaye(MSc, PhD) (advisor).

Subjects/Keywords: Hepatitis B virus (HBV); hepatitis C virus (HCV); (HIV); syphilis

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Jijiga, E. (2014). Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia. (Thesis). Addis Ababa University. Retrieved from http://etd.aau.edu.et/dspace/handle/123456789/5846

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Jijiga, Edosa. “Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia. ” 2014. Thesis, Addis Ababa University. Accessed March 02, 2021. http://etd.aau.edu.et/dspace/handle/123456789/5846.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Jijiga, Edosa. “Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia. ” 2014. Web. 02 Mar 2021.

Vancouver:

Jijiga E. Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia. [Internet] [Thesis]. Addis Ababa University; 2014. [cited 2021 Mar 02]. Available from: http://etd.aau.edu.et/dspace/handle/123456789/5846.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Jijiga E. Assessment of Transfusion Transmissible Infections Among Blood Donors (A six years study) and Strategy on Direct Laboratory Testing Cost of Blood Screening at National Blood Transfusion Service of Addis Ababa, Ethiopia. [Thesis]. Addis Ababa University; 2014. Available from: http://etd.aau.edu.et/dspace/handle/123456789/5846

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations